Bug DNA Storage Gadget Gets FDA Classification
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting microbial nucleic acid storage and stabilization devices into class II, meaning they’ll have special safety rules but less red tape. This change helps companies bring these devices to market faster while keeping patients safe. It affects manufacturers and healthcare providers starting May 9, 2025, and aims to boost innovation without extra costs.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Device moved to Class II (special controls)
The FDA has officially classified microbial nucleic acid storage and stabilization devices as Class II (special controls). The final order is effective May 9, 2025 (the classification was applicable March 19, 2018). FDA says this change will reduce regulatory burdens and help patients get innovative devices faster.
Device subject to 510(k) premarket notification
Under this classification, the device is subject to premarket notification under section 510(k) of the FD&C Act rather than automatic Class III premarket approval. This allows sponsors to use the 510(k) pathway and, when applicable, for this device to serve as a predicate for future 510(k) submissions.
New labeling and validation requirements for makers
Manufacturers must meet specific special controls in 21 CFR 866.2950, including labeling that lists microorganisms and specimen types, a detailed device description, performance data including nucleic acid stability and microorganism inactivation, limiting statements about compatibility and validation scope, and design verification/validation including limit of detection information.
Special controls address false negatives and inactivation risks
FDA identified risks to health such as false negative results from failure to stabilize nucleic acid and risks from failure to inactivate specimens. FDA states that the general controls plus the named special controls will mitigate these risks and provide reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Measure Non-Microbial Analytes To Aid in the Detection and Identification of Localized Human Infections
The FDA is officially putting devices that detect and measure non-microbial markers to find localized infections into a safer, more manageable category called Class II. This change, effective May 9, 2025, means these devices will face fewer regulatory hurdles, making it easier and faster for patients to get access to new, helpful infection-detecting tools. Companies making these devices will now follow special safety rules but avoid the toughest approval process, saving time and money.
Next: 2025-08146, Medical Devices; Immunology and Microbiology Devices; Classification of the Cytomegalovirus Nucleic Acid Detection Device for Congenital Cytomegalovirus Infection
The FDA is officially classifying a special test that detects cytomegalovirus (CMV) in newborns as a Class II device, meaning it has special safety rules but is easier to get to patients. This change helps make sure the test is safe and effective while speeding up access to this important tool for babies and families. The new rules took effect on May 9, 2025, and could lower costs and delays for companies making these tests.